These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26419285)

  • 1. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.
    Doshi N; Demeule B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
    Tomlinson A; Demeule B; Lin B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
    Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
    J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Silicone Oil on Free Fatty Acid Particle Formation due to Polysorbate 20 Degradation.
    Fish R; Lin J; Doshi N
    Pharm Res; 2020 Oct; 37(11):216. PubMed ID: 33029664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution of Polysorbate 20 Degradation Related Free Fatty Acid Particles in Intravenous Bag Solutions.
    Doshi N; Rutherford K; Najjar A
    J Pharm Sci; 2021 Feb; 110(2):687-692. PubMed ID: 33039438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymatic degradation pattern of polysorbate 20 impacts interfacial properties of monoclonal antibody formulations.
    Gregoritza K; Theodorou C; Heitz M; Graf T; Germershaus O; Gregoritza M
    Eur J Pharm Biopharm; 2024 Jan; 194():74-84. PubMed ID: 38042510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method.
    Zhang S; Riccardi C; Kamen D; Xiao H; Li N
    Anal Biochem; 2022 Jan; 637():114472. PubMed ID: 34801481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glass Leachables as a Nucleation Factor for Free Fatty Acid Particle Formation in Biopharmaceutical Formulations.
    Allmendinger A; Lebouc V; Bonati L; Woehr A; Kishore RSK; Abstiens K
    J Pharm Sci; 2021 Feb; 110(2):785-795. PubMed ID: 33035535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
    Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
    Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway.
    Saggu M; Liu J; Patel A
    Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.